{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:58:37Z","timestamp":1769572717767,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bone.2019.115113","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T12:10:33Z","timestamp":1571746233000},"page":"115113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial"],"prefix":"10.1016","volume":"130","author":[{"given":"David L.","family":"Kendler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Geusens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"L\u00f3pez-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-8518","authenticated-orcid":false,"given":"Eric","family":"Lespessailles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bone.2019.115113_bib0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11926-008-0019-4","article-title":"Drug-induced osteoporosis: beyond glucocorticoids","volume":"10","author":"Briot","year":"2008","journal-title":"Curr. Rheumatol. Rep."},{"issue":"10","key":"10.1016\/j.bone.2019.115113_bib0010","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","article-title":"Drug-induced osteoporosis: mechanisms and clinical implications","volume":"123","author":"Mazziotti","year":"2010","journal-title":"Am. J. Med."},{"issue":"22","key":"10.1016\/j.bone.2019.115113_bib0015","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/2013.jamainternmed.469","article-title":"The risk of hip fracture after initiating antihypertensive drugs in the elderly","volume":"172","author":"Butt","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.bone.2019.115113_bib0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamapsychiatry.2017.0449","article-title":"Association of mental disorders and related medication use with risk for major osteoporotic fractures","volume":"74","author":"Bolton","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.bone.2019.115113_bib0025","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00198-005-0065-y","article-title":"Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture","volume":"17","author":"Vestergaard","year":"2006","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.115113_bib0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4065\/mcp.2010.0636","article-title":"Update on medications with adverse skeletal effects","volume":"86","author":"Davidge Pitts","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"10117","key":"10.1016\/j.bone.2019.115113_bib0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2019.115113_bib0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2019.115113_bib0045","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2019.115113_bib0050","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamainternmed.2016.4814","article-title":"Patterns of prescription drug use before and after fragility fracture","volume":"176","author":"Munson","year":"2016","journal-title":"JAMA Intern. Med."},{"issue":"9","key":"10.1016\/j.bone.2019.115113_bib0055","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative","volume":"170","author":"Gray","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.bone.2019.115113_bib0060","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11606-008-0525-0","article-title":"Depressive symptoms, bone loss, and fractures in postmenopausal women","volume":"23","author":"Spangler","year":"2008","journal-title":"J. Gen. Intern. Med."},{"issue":"9","key":"10.1016\/j.bone.2019.115113_bib0065","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1210\/jc.2010-0861","article-title":"Update in serotonin and bone","volume":"95","author":"Bliziotes","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2019.115113_bib0070","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jbmr.1554","article-title":"Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis","volume":"27","author":"Eom","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00198-012-2015-9","article-title":"Relationship between use of antidepressants and risk of fractures: a meta-analysis","volume":"24","author":"Rabenda","year":"2013","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00198-015-3213-z","article-title":"Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study","volume":"27","author":"Wang","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2019.115113_bib0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-018-4413-0","article-title":"Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2019.115113_bib0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archinte.167.2.188","article-title":"Effect of selective serotonin reuptake inhibitors on the risk of fracture","volume":"167","author":"Richards","year":"2007","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.bone.2019.115113_bib0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e31817e0ecb","article-title":"Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures","volume":"28","author":"Ziere","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.bone.2019.115113_bib0100","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1002\/gps.4667","article-title":"Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer\u2019s disease","volume":"32","author":"Torvinen-Kiiskinen","year":"2017","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"7","key":"10.1016\/j.bone.2019.115113_bib0105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1060028016644466","article-title":"Antidepressant Use and recurrent falls in community-dwelling older adults: findings from the health ABC study","volume":"50","author":"Marcum","year":"2016","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00198-013-2446-y","article-title":"Association between use of benzodiazepines and risk of fractures: a meta-analysis","volume":"25","author":"Xing","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.115113_bib0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.maturitas.2013.01.004","article-title":"Psychotropic medications, including short acting benzodiazepines, strongly increase the frequency of falls in elderly","volume":"74","author":"van Strien","year":"2013","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.bone.2019.115113_bib0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","article-title":"Increase in vertebral fracture risk in postmenopausal women using omeprazole","volume":"84","author":"Roux","year":"2009","journal-title":"Calcif. Tissue Int."},{"issue":"4","key":"10.1016\/j.bone.2019.115113_bib0130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00223-018-0432-2","article-title":"Proton pump inhibitor use, H2-Receptor antagonist use, and risk of incident clinical vertebral fracture in women","volume":"103","author":"Paik","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00198-018-4788-y","article-title":"Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies","volume":"30","author":"Poly","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"24","key":"10.1016\/j.bone.2019.115113_bib0140","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.bone.2019.115113_bib0145","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","article-title":"Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial","volume":"118","author":"O\u2019Connell","year":"2005","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.bone.2019.115113_bib0150","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/jbmr.108","article-title":"Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial","volume":"25","author":"Wright","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2019.115113_bib0155","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","article-title":"Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium","volume":"12","author":"Ito","year":"2010","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"2","key":"10.1016\/j.bone.2019.115113_bib0160","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jbmr.2344","article-title":"Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study","volume":"30","author":"Solomon","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2019.115113_bib0165","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/jbmr.2279","article-title":"Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study","volume":"29","author":"Lewis","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12603-016-0679-0","article-title":"Association of proton pump inhibitor use with recurrent falls and risk of fractures in older women: a study of medication use in older fallers","volume":"20","author":"Thaler","year":"2016","journal-title":"J. Nutr. Health Aging"},{"issue":"6","key":"10.1016\/j.bone.2019.115113_bib0175","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2125.2004.02078.x","article-title":"Bisphosphonate use and subsequent prescription of acid suppressants","volume":"57","author":"Roughead","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0180","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jbmr.2011","article-title":"Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study","volume":"29","author":"Prieto-Alhambra","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2019.115113_bib0185","first-page":"38","article-title":"The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis","volume":"101","author":"McGowan","year":"2008","journal-title":"Ir. Med. J."},{"issue":"11","key":"10.1016\/j.bone.2019.115113_bib0190","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinternmed.2011.20","article-title":"Proton pump inhibitor use and the antifracture efficacy of alendronate","volume":"171","author":"Abrahamsen","year":"2011","journal-title":"Arch. Intern. Med."},{"issue":"12","key":"10.1016\/j.bone.2019.115113_bib0195","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00198-009-0891-4","article-title":"Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates","volume":"20","author":"de Vries","year":"2009","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.115113_bib0200","first-page":"4899","article-title":"Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis","volume":"8","author":"Yang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.bone.2019.115113_bib0205","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00198-011-1574-5","article-title":"Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors","volume":"23","author":"Roux","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2019.115113_bib0210","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bone.2019.115113_bib0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamainternmed.2015.8581","article-title":"Changes in prescription and over-the-Counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011","volume":"176","author":"Qato","year":"2016","journal-title":"JAMA Intern. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219304065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:44:19Z","timestamp":1757612659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219304065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":43,"alternative-id":["S8756328219304065"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.115113","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.115113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115113"}}